AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated April 3rd, 2020

AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant

NOW
PLAYING
Symptoms of Relapse in Acute Myeloid Leukemia (AML)
NOW
PLAYING
Acute Myeloid Leukemia (AML): Treatment Options After Relapse
NOW
PLAYING
What is The Treatment For Acute Myeloid Leukemia (AML) Patients After Relapse: Gilteritinib And FLT3 Inhibitors
NOW
PLAYING
What Are The Options For Patients When Acute Myeloid Leukemia Returns?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.